High Specificity in Circulating Tumor Cell Identification Is Required for Accurate Evaluation of Programmed Death-Ligand 1Jennifer L. Schehr, Joshua M. Lang, Erika Héninger et al.|PLoS ONE|2016Cited by 63
Versatile exclusion-based sample preparation platform for integrated rare cell isolation and analyte extractionHannah M. Pezzi, David J. Beebe, David J. Guckenberger et al.|Lab on a Chip|2018Cited by 25
Abstract 1602: Development and validation of an NGS-based assay to detect all classes of genomic alterations in circulating tumor cells (CTCs) from patients with solid tumorsAllison W. Welsh, Philip J. Stephens, Garrett M. Frampton et al.|Cancer Research|2015Cited by 0